Medical Doctor Program year 2020 Reported 2019–2020 Source: CMS Open Payments, 2026 publication

Herbert Chin

Psychiatry Whittier, CA Medical Doctor

NPI 1336198373 CMS profile 151059

9209 Colima Rd Ste 3600, Whittier, Whittier, CA 90605

Open in the dashboard

General payments

$3,251

239 records reported · program years 2019–2020

Research payments

$0

Paid to them · None reported · program years 2019–2020

Ownership & investment interest

$0

None reported

Through program year 2020, Herbert Chin of Whittier, CA is reported in the CMS Open Payments database as having received $3,251 across 239 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 85th percentile of Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

2 rows
Year Kind Relative to this record's peak year Amount Records
2020 General $1,656 113
2019 General $1,596 126

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Herbert Chin
  • Psychiatry median
  • Middle half of Psychiatry
  • National median

In program year 2025, general payments to Herbert Chin were reported at $0. Among 14,155 Psychiatry profiles paid that year, the median was $180 and the middle half received between $58 and $685.

Show as a table
Year Herbert Chin Psychiatry median Middle half National median
2019 $1,596 $184 $59–$605 $163
2020 $1,656 $119 $36–$372 $114
2021 $0 $143 $43–$576 $132
2022 $0 $153 $50–$590 $149
2023 $0 $170 $56–$651 $160
2024 $0 $179 $57–$673 $164
2025 $0 $180 $58–$685 $169

Breakdown

Who paid General payments · program years 2019–2020
  1. Allergan Inc. $888 89 payments
  2. Otsuka America Pharmaceutical, Inc. $527 34 payments
  3. Teva Pharmaceuticals USA, Inc. $476 52 payments
  4. Janssen Pharmaceuticals, Inc $459 18 payments
  5. Vanda Pharmaceuticals Inc. $348 19 payments
  6. Takeda Pharmaceuticals U.S.A., Inc. $197 9 payments
  7. Adlon Therapeutics L.P. $82 4 payments
  8. Bausch Health US, LLC $54 3 payments
  9. Lundbeck LLC $50 3 payments
  10. Avanir Pharmaceuticals, Inc. $44 2 payments
  11. Other $126 6 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2020
  1. Food and Beverage $3,251 239 payments
Products named General payments · program years 2019–2020
  1. VRAYLAR $888 89 payments
  2. REXULTI Psychiatry $527 34 payments
  3. AUSTEDO $476 52 payments
  4. SPRAVATO $440 17 payments
  5. HETLIOZ $348 19 payments
  6. FANAPT $291 17 payments
  7. ADHANSIA XR $82 4 payments
  8. VYVANSE $61 3 payments
  9. APLENZIN $54 3 payments
  10. REXULTI Psychiatry $50 3 payments
  11. Other $314 15 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

239 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Psychiatry in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2020

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record